Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Find the right bone cancer treatment regimen with detailed instructions on selection, dosing, and administration of anti-cancer agents such as vincristine.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Researchers plan to initiate a phase 2 trial of the vaccine, which will enroll up to 25 patients with metastatic chordoma.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified